Please insert the following in the first sentence of the application — This application is a continuation of U.S. application no. 08/377, 798, filed January 24, 1995, now abandoned, which is a continuation-in-part of U.S. application no. 08/253,663, filed May 3, 1995, now abandoned.

IN THE CLAIMS:

Please cancel claims 1-24, 28-30, 35-38, 40, 42-70 and 75 without prejudice.

71. A method for treating or inhibiting atherosclerosis in a mammal comprising:

providing an agent for inhibiting an interaction between P-selectin and a ligand of P-selectin and between E-selectin and a ligand of E-selectin; and

administering said agent to a mammal in need of such treatment so as to cause such inhibition to occur, wherein said agent is selected from the group consisting of PSGL-1, soluble forms of PSGL-1, fragments of PSGL-1, and mimetics of PSGL-1.

- 72. The method of claim 71 wherein said P-selectin is on a cell.
- 73. The method of claim 72 wherein said cell is an endothelial cell.
- 74. The method of claim 71 wherein said ligand of P-selectin comprises a glycoprotein.
- 76. The method of claim 71 wherein said ligand of P-selectin is selected from the group consisting of sialyl-Lewis x, sialyl-Lewis a, sialyl-Lewis-x-pentasaccharide, polyactosaminoglean, carbohydrate containing 2,6 sialic acid, Lewis x 3'-0-sulfate, heparin oligosaccharides, PSGL-1, 160 kD monospecific P-selectin ligand and lysosomal membrane glycoproteins.
- 77. The method of claim 71 wherein said ligand of P-selectin is on a cell, selected from the group consisting of monocytes, neutrophils, eosinophils, CD+4 T cells, CD+8 T cells, and natural killer cells.

- 78. The method of claim 71 wherein said ligand of P-selectin is on a leukocyte.
- 79. The method of claim 78 wherein said leukocyte is a neutrophil.
- 80. The method of claim 78 wherein said leu8kocyte is a monocyte.
- 81. The method of claim 71 wherein said P-selectin can bind to said ligand in the absence of said agent.
- 82. The method of claim 71 wherein said agent is PSGL-1.
- 83. The method of claim 71, wherein said agent is administered in sequential exposures over a period of hours, days, weeks months or years.
- 84. The method of claim 71, wherein said agent is administered repeatedly, or by a controlled release delivery system.
- 85. The method of claim 71, wherein said agent is administered in combination with other therapeutic agents.

Please add the following new claims:

- 86. The method of claim 72 wherein said cell is a platelet.
- The method of claim 71 wherein said mammal is a human.
- 88. The method of claim 71 wherein said agent is administered at a dose of from about 0.01 mg/kg to about 200 mg/kg of body weight.